Basel Shoua

Hematologist/Oncologist, TMC Cancer Center

[Michael May @MichaelMayMD]

Practice changing EMERALD-3 trial: STRIDE improved PFS from 8.1 to 12.9 months in patients with HCC treated with TACE. Lenvatinib appears to add no additional benefit with added toxicity. @GABOUALFA @MSKCancerCenter @MSK_DeptOfMed

[Basel Shoua @Baselsho]

What an incredible man!

[Dr Amol Akhade @SuyogCancer]

How to the treatment algorithm is shaping up in ES-SCLC and upcoming ADC in SCLC . Nice talk by @peters_solange #elcc26

[Haluk Kavus, MD @HKavusMD]

I created a Hematopathology High-Yield Board Review Series.
Here is part 1!
https://t.co/HNFNFyPsiR

#Pathology #Boardreview #Hematology #Hematopathology #Pathresidents

[Arndt Vogel @ArndtVogel]

Immune-mediated AEs and OS with STRIDE and durvalumab in unresectable HCC: HIMALAYA phase III randomized clinical trial
@HEP_Journal
10.1097/HEP.0000000000001385
👉Pts who experienced imAEs with STRIDE, but not Durva had better outcome
🧐same as with Nivo/Ipi
@myESMO @ASCO @ilca @EASLnews

[Basel Shoua @Baselsho]

@Jake__Wujastyk @gork how low solana will go sub 100 ?

[Oncology Brothers @OncBrothers]

One page takeaway/summary from our 🗣️ with @VincentRK on #AQUILA study that resulted in #Daratumumab @FDAOncology approval on November 6, 2025 for smoldering myeloma!

#OncTwitter #mmsm #MedTwitter @OncUpdates #HemeTwitter

[Arndt Vogel @ArndtVogel]

Management of Cancer During Pregnancy: ASCO Guideline
@JCO_ASCO
https://t.co/KZTF4OHCuS
👏Very useful guidance on the recommended management of cancer in pregnant patients
👉Systematic review of 450 studies
👉Many systemic therapies are contraindicated
@myESMO @ASCO

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 Poor PS, high PD-L1—can IO still work?

IFCT-1802 SAVIMMUNE (Ph2) evaluated 1L durvalumab in stage IV #NSCLC with ECOG PS 2–3 & PD-L1 ≥25%.

◼️ Grade ≥3 TRAEs (8 wks): 10%
◼️ ORR: 26%
◼️ 1-yr OS: 40%
◼️ PS improvement at 8 wks: 44%

Important data for a population often excluded from trials. @LungCancerRx @OncoAlert @oncodaily
@JTOonline https://t.co/slBfnKXnLc

[Keith Siau @drkeithsiau]

Cancer of unknown primary - pathophysiology and tissue markers 💡

https://t.co/wOFlmO56Jy

[Basel Shoua @Baselsho]

@doepke_michel Grok is this good ?

[Dr Amol Akhade @SuyogCancer]

Is perioperative IO way forward in early HCC ? 🤔 any thoughts? @GIMedOnc @NiuSanford @CathyEngMD @ASCO #ASCOGI26 @GIcancerDoc @GABOUALFA

[Grainne O'Kane @graokane]

Updated CheckMate 9DW #HCC
Nivo+ipi v len/sor
➡️follow up 52mths
➡️1 in 4 pts BCLC B
➡️mOS 23.7 v 20.6mths;
➡️48mth OS rates 31 v18%
➡️G3/4 TRAEs 25 v 13%
⭐️interesting hepatitis data 19% early event ~6 weeks ‼️close monitoring
@ASCO @OncoAlert @ILCAnews

[Grainne O'Kane @graokane]

KEYNOTE-937- adj pembro v placebo #HCC
➡️ 2nd -ve trial; n=959, mFU 50.7mths
➡️ maj viral aetiology; 77% AFP<200, 83% BCLCA
➡️mRFS 46.7 v 45.5mo, mOS NR either arm
➡️≥G3 AEs 32 v 22%
higher mRFS than IMBrave050 & STORM
@ASCO @ILCAnews @EASLnews @OncoAlert #GI26

[Grainne O'Kane @graokane]

ABC-HCC ph3b, TACE-eligible #HCC(+VP1/2)
➡️Atezo/Bev v TACE
➡️206/320 enrolled-IA reports n=168
➡️mTTFS (time failure tx strategy) 14.6 v 9.5mo, HR 0.54
➡️≥G3 AEs 33% v 15%
??More 🔧#HCC intermediate stage holy grail!!
#G26 @ASCO @myESMO @OncoAlert @ILCAnews @EASLnews

[Grainne O'Kane @graokane]

Liver Power Hour 👏 #HCC #GI26
MDT 3 cases with learning pts 👇
1. Post LT recurrence-‼️challenging Surgery/LRT where possible
2. BCLC B options- Surgery/LRT(Y90/SBRT/TACE)/systemic
3. Single lesion VP1/2 -getting to Sx Y90 v Systemic-note high risk recurrence @ASCO @OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

#GI26 ABC-HCC (phase IIIb) | Intermediate-stage HCC
🔀 Atezolizumab + bevacizumab vs TACE (head-to-head)
⏳ TTFS: 14.6 vs 9.5 mo → HR 0.55 (95% CI 0.36–0.83)
➡️ First interim analysis suggests systemic atezo/bev outperforms TACE in BCLC B HCC.
@OncoAlert @larvol

[Basel Shoua @Baselsho]

The Power of “I Don't Know” | Journal of Clinical Oncology https://t.co/9qzZ4fZLXZ

[Ilana Schlam @IlanaSchlam]

In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC.
@DFCI_BreastOnc #SABCS25

[Dr Rishabh Jain @DrRishabhOnco]

🚨 ONCO EMERGENCY: How to Manage EXTRAVASATION in 30 Seconds 🩺💉

Extravasation of chemotherapy = oncology emergency.
Early recognition + immediate action = tissue saved.

Here’s the crisp, protocol-ready approach 👇

1️⃣ STOP Immediately
❌ Stop infusion
❌ Do not flush
✔️ Leave cannula in situ
✔️ Aspirate as much drug as possible
✔️ Mark the area + click a photo

2️⃣ Identify the Agent
Classify the drug:

🔥 Vesicant (DNA-binding / Non-DNA)
😣 Irritant
🙂 Non-vesicant

(Anthracyclines, Vinca alkaloids, Taxanes, Platinum, Mitomycin etc.)

3️⃣ Two Key Pathways

A) “Localise & Neutralise” – DNA-Binding Vesicants
(Anthracyclines, Mitomycin, Dactinomycin)
❄️ COLD compress 20 min × 4/day × 1–2 days

💊 Antidotes:
<3 ml anthracycline → Topical DMSO
3 ml anthracycline → Dexrazoxane (Savene) within 6 hrs
Mitomycin → DMSO

B) “Disperse & Dilute” – Non-DNA Binding Vesicants
(Vinca alkaloids, Taxanes, Trabectedin)
🔥 WARM compress 20 min × 4/day × 1–2 days
💉 Hyaluronidase 150–1500 IU SC around site (5 injections)

4️⃣ Elevate, Analgesia, Plastics Referral
✋ Elevate limb
💊 Analgesics if required
🏥 Early plastics/flush-out team for large-volume or CVAD extravasa
tion

5️⃣ Follow-Up
Mandatory review within 1 week

Patient counselling: monitor for redness, blistering, worsening pain

Document EVERYTHING (site, size, drug, photo, interventions)

💡 TAKE-HOME
Extravasation is rare but high-stakes.
Most injuries are preventable with:
Good venous access
Trained staff
Fast action
Correct antidote pathway
Oncology teams save tissue before they save time. ⏱️🩺

🔖 Save this. Share with your residents and healthcare staff.

#OncoTwitter #MedTwitter #ChemoSafety #Nursing #Oncology @myESMO @OncoAlert @ESMO_Open @asco